Cenix signs RNAi research agreement with SYGNIS
21-Nov-2011
- Germany
“We are delighted to enter into this new relationship with SYGNIS,” noted Dr. Christophe Echeverri, CEO/CSO of Cenix. “This project, and the many others like it now ongoing here and throughout the industry, continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets”.
Financial terms were not disclosed.
Most read news
Organizations
Cenix BioScience
Expedeon
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.